RE: Moonparty26 Apr 2020 08:12
its all about the priming ............... If you want a potent T cell then you have to prime the system correctly ..
SCIB1 melanoma Vaccine using Immunobody has proved that the T cells generated are Potent ... without the need to make a ****tail because the vaccine generates an antibody on one side by converting a muscle cell into a factory producing more of the same antibody. At the injection site stray Dendritic Cells will also be near these are also opened up by the electric field or high speed nano particles (fired into the cell) these cells then digest the vaccine and present the information to T cells but the antibodies from the muscles cell also engage with the Dendritic cell and cross present the information again to the dc ... this is called Cross presentation so This Dendritic cell has now received 2 instructions and it enables t cells to receive the information to form "very High Binding" to its target .. in this case it would be the virus or cells infected with the virus. It also slews the T cell to high inflammatory in other words the T cells leach powerful cytokines to attract others to the site of infection and because the T cells Bind even with low expression of the target .. they can kill easily ...
so that is why Scancell rave about Cross Presentation
For the induction of antigen-specific CD8+ T cells, antigen needs to be presented in MHC class I molecules in order to be recognized by the TCR/CD3 complex on CD8+ T cells. Peptides derived from endogenous proteins degraded in the cytosol, that are transported into the endoplasmic reticulum (ER), are loaded on MHC class I molecules, which will be transported to the plasma membrane as a stable peptide–MHC class I complex (1). The presentation of endogenous-derived peptides allows the immune system to detect cells that present altered self peptides or foreign peptides and is therefore an important defense mechanism against cancer or viruses (2). Although peptide–MHC class I complexes can be directly recognized by naïve CD8+ T cells, these cells require adequate co-stimulation from antigen-presenting cells (APCs) in order to become potent effector CD8+ T cells with cytotoxic potential. Besides, APCs can also encounter exogenous antigens, namely of microbial or tumor origin, which they internalize for processing and presentation in MHC class I molecules, a phenomenon known as antigen cross-presentation.
Although multiple APCs are able to cross-present antigens, dendritic cells (DCs) are the most efficient cells in vivo (3–5). The potential of DCs to cross-present antigen has initiated many research questions aimed at finding strategies to enhance cross-presentation of DCs in order to improve tumor- and viral-specific CD8+ T cell responses for the treatment of cancer or infectious diseases. Several questions remain unanswered, such as the molecular basis for the differences in cross-presentation efficiency observed amongst different DC subsets
Sign In
Follow the stocks
